Banner

RLE with new accommodative IOL offers good distance, near vision

Article

Six-month results show 88% achieving 20/40 for distance, 70% achieving J3 or better

Related Videos
Related Content

Outlook Therapeutics requests Type A meeting with FDA

September 29th 2023

EyePod: Transforming the MIGS pipeline into clinical reality

September 26th 2023

BLOG: MicroPulse TLT for patients who struggle with drops

September 29th 2023

EyePod: Week in Review - September 17, 2023

September 23rd 2023

Kriya announces exclusive license, collaboration, agreement with Everads to advance gene therapies for diseases in ophthalmology, Including GA

September 28th 2023

Treating anisometropic amblyopia in Argentinian patients with a dichoptic digital platform

September 28th 2023

Outlook Therapeutics requests Type A meeting with FDA

September 29th 2023

EyePod: Transforming the MIGS pipeline into clinical reality

September 26th 2023

BLOG: MicroPulse TLT for patients who struggle with drops

September 29th 2023

EyePod: Week in Review - September 17, 2023

September 23rd 2023

Kriya announces exclusive license, collaboration, agreement with Everads to advance gene therapies for diseases in ophthalmology, Including GA

September 28th 2023

Treating anisometropic amblyopia in Argentinian patients with a dichoptic digital platform

September 28th 2023

Outlook Therapeutics requests Type A meeting with FDA

September 29th 2023

EyePod: Transforming the MIGS pipeline into clinical reality

September 26th 2023

BLOG: MicroPulse TLT for patients who struggle with drops

September 29th 2023

EyePod: Week in Review - September 17, 2023

September 23rd 2023

Kriya announces exclusive license, collaboration, agreement with Everads to advance gene therapies for diseases in ophthalmology, Including GA

September 28th 2023

Treating anisometropic amblyopia in Argentinian patients with a dichoptic digital platform

September 28th 2023
© 2023 MJH Life Sciences

All rights reserved.